Logotype for Dimed S.A. Distribuidora de Medicamentos

Dimed (PNVL3) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Dimed S.A. Distribuidora de Medicamentos

Q3 2026 earnings summary

9 Nov, 2026

Executive summary

  • 3Q26 retail gross revenue reached R$1.699bn, up 15.3% YoY; adjusted EBITDA rose 21.2% to R$96.8m and adjusted net income increased 35.4% to R$46.4m.

  • Positive free cash flow continued for a seventh consecutive quarter, while net debt/adjusted LTM EBITDA declined to 0.8x.

  • Digital engagement, store productivity and Southern Region market-share gains supported results; management remained confident in the Plan 2030 and a strong 2026 close.

Financial highlights

  • Consolidated gross revenue was R$1.705bn, up 15.3% YoY; 9M26 gross revenue reached R$4.911bn, up 15.6%.

  • Adjusted EBITDA was R$96.8m, with a 5.7% margin; adjusted net income was R$46.4m, with a 2.7% margin.

  • Retail gross margin was 29.7%, down 0.2 p.p. YoY; selling expenses grew 12.0%, below sales growth, and diluted 0.7 p.p.

  • 3Q26 operating cash flow was R$64.9m and free cash flow was R$19.9m, up 24.2% YoY.

Outlook and guidance

  • 2030 ambitions include revenue of R$11.5bn–R$12bn, EBITDA margin of 6.7%–7% and up to 1,000 stores.

  • Management expects two-digit Q4 sales growth despite a high comparison base; Black Friday and Christmas are key seasonal opportunities.

  • Store expansion is set to continue, with renewed acceleration in 3Q26 and interior locations in Southern states identified as opportunities.

  • Expense control, store and logistics productivity, automation and AI are expected to support efficiency; continued net debt reduction is planned.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Dimed